Showing results (31-40 of 55) with videos related to
Sort By:
Pageof 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2005
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancerC P Belani, J S Lee, M A Socinski, et al.Anti-Cancer Drugs|October 17, 1998
Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patientsM A Socinski, P N Mudd, K M Radomski, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2009
A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)M A Socinski, M N Saleh, D F Trent, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 22, 2016
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancerL Paz-Ares, M A Socinski, J Shahidi, et al.American Journal of Clinical Oncology|February 1, 1994
Neoadjuvant treatment of stage IIIA non-small cell lung cancer. Long-term resultsA D Elias, A T Skarin, R Gonin, et al.Archives of Internal Medicine|March 1, 1983
Pure RBC aplasia and myasthenia gravis. Coexistence of two diseases associated with thymomaM A Socinski, W B Ershler, J P Frankel, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2013
Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancerM A Socinski, I Okamoto, J K Hon, et al.The New England Journal of Medicine|September 8, 1988
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppressionK S Antman, J D Griffin, A Elias, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 6, 2012
Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancerM A Socinski, C J Langer, I Okamoto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancerM A Socinski, A B Sandler, L L Miller, et al.Pageof 6